Minimal residual disease in multiple myeloma: Benefits of flow cytometry
Irina Galtseva(National Research Center for Preventive Medicine), Л. П. Менделеева(National Research Center for Hematology Russian Academy of Medical Sciences), Yulia Davydova(National Research Center for Preventive Medicine), Hunan Julhakyan(National Research Center for Preventive Medicine), Н. М. Капранов(National Research Center for Preventive Medicine)
Cited by 10
Related Papers
Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation
|Bone Marrow Transplantation|2014|195
Atlas of RNA sequencing profiles for normal human tissues
|Scientific Data|2019|142
Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective
|The Oncologist|2010|92
Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulability in patients with multiple myeloma
|Leukemia & lymphoma/Leukemia and lymphoma|2015|59